160 related articles for article (PubMed ID: 16835908)
1. Evolutionary identification of a subtype specific functional site in the ligand binding domain of steroid receptors.
Raviscioni M; He Q; Salicru EM; Smith CL; Lichtarge O
Proteins; 2006 Sep; 64(4):1046-57. PubMed ID: 16835908
[TBL] [Abstract][Full Text] [Related]
2. A conserved surface on the ligand binding domain of nuclear receptors for allosteric control.
Buzón V; Carbó LR; Estruch SB; Fletterick RJ; Estébanez-Perpiñá E
Mol Cell Endocrinol; 2012 Jan; 348(2):394-402. PubMed ID: 21878368
[TBL] [Abstract][Full Text] [Related]
3. A family-based approach reveals the function of residues in the nuclear receptor ligand-binding domain.
Folkertsma S; van Noort P; Van Durme J; Joosten HJ; Bettler E; Fleuren W; Oliveira L; Horn F; de Vlieg J; Vriend G
J Mol Biol; 2004 Aug; 341(2):321-35. PubMed ID: 15276826
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and in vitro biological evaluation of small molecule inhibitors of estrogen receptor alpha coactivator binding.
Rodriguez AL; Tamrazi A; Collins ML; Katzenellenbogen JA
J Med Chem; 2004 Jan; 47(3):600-11. PubMed ID: 14736241
[TBL] [Abstract][Full Text] [Related]
5. An evolutionary trace method defines binding surfaces common to protein families.
Lichtarge O; Bourne HR; Cohen FE
J Mol Biol; 1996 Mar; 257(2):342-58. PubMed ID: 8609628
[TBL] [Abstract][Full Text] [Related]
6. Correlated evolutionary pressure at interacting transcription factors and DNA response elements can guide the rational engineering of DNA binding specificity.
Raviscioni M; Gu P; Sattar M; Cooney AJ; Lichtarge O
J Mol Biol; 2005 Jul; 350(3):402-15. PubMed ID: 15946684
[TBL] [Abstract][Full Text] [Related]
7. The conserved residue Phe273(282) of PPARalpha(gamma), beyond the ligand-binding site, functions in binding affinity through solvation effect.
Yue L; Ye F; Xu X; Shen J; Chen K; Shen X; Jiang H
Biochimie; 2005 Jun; 87(6):539-50. PubMed ID: 15935279
[TBL] [Abstract][Full Text] [Related]
8. Structural insight into the specific interaction between murine SHPS-1/SIRP alpha and its ligand CD47.
Nakaishi A; Hirose M; Yoshimura M; Oneyama C; Saito K; Kuki N; Matsuda M; Honma N; Ohnishi H; Matozaki T; Okada M; Nakagawa A
J Mol Biol; 2008 Jan; 375(3):650-60. PubMed ID: 18045614
[TBL] [Abstract][Full Text] [Related]
9. Understanding the human estrogen receptor-alpha using targeted mutagenesis.
Skafar DF; Koide S
Mol Cell Endocrinol; 2006 Feb; 246(1-2):83-90. PubMed ID: 16442702
[TBL] [Abstract][Full Text] [Related]
10. Functional characterization of the native NH2-terminal transactivation domain of the human androgen receptor: binding kinetics for interactions with TFIIF and SRC-1a.
Lavery DN; McEwan IJ
Biochemistry; 2008 Mar; 47(11):3352-9. PubMed ID: 18284209
[TBL] [Abstract][Full Text] [Related]
11. Insights into ligand selectivity in estrogen receptor isoforms: molecular dynamics simulations and binding free energy calculations.
Zeng J; Li W; Zhao Y; Liu G; Tang Y; Jiang H
J Phys Chem B; 2008 Mar; 112(9):2719-26. PubMed ID: 18266357
[TBL] [Abstract][Full Text] [Related]
12. Small-angle X-ray scattering studies on structures of an estrogen-related receptor alpha ligand binding domain and its complexes with ligands and coactivators.
Jin KS; Park JK; Yoon J; Rho Y; Kim JH; Kim EE; Ree M
J Phys Chem B; 2008 Aug; 112(32):9603-12. PubMed ID: 18646811
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of the ligand binding site of the human galanin receptor type 2, identifying subtype selective interactions.
Lundström L; Sollenberg UE; Bartfai T; Langel U
J Neurochem; 2007 Dec; 103(5):1774-84. PubMed ID: 17953676
[TBL] [Abstract][Full Text] [Related]
14. A pharmacophore-based evolutionary approach for screening selective estrogen receptor modulators.
Yang JM; Shen TW
Proteins; 2005 May; 59(2):205-20. PubMed ID: 15726586
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the Nurr1 ligand-binding domain co-activator interaction surface.
Volakakis N; Malewicz M; Kadkhodai B; Perlmann T; Benoit G
J Mol Endocrinol; 2006 Oct; 37(2):317-26. PubMed ID: 17032747
[TBL] [Abstract][Full Text] [Related]
16. Implications of the binding of tamoxifen to the coactivator recognition site of the estrogen receptor.
Kojetin DJ; Burris TP; Jensen EV; Khan SA
Endocr Relat Cancer; 2008 Dec; 15(4):851-70. PubMed ID: 18755852
[TBL] [Abstract][Full Text] [Related]
17. Field-based comparison of ligand and coactivator binding sites of nuclear receptors.
Wohlfahrt G; Sipilä J; Pietilä LO
Biopolymers; 2009 Oct; 91(10):884-94. PubMed ID: 19582836
[TBL] [Abstract][Full Text] [Related]
18. Receptor binding characteristics of the endocrine disruptor bisphenol A for the human nuclear estrogen-related receptor gamma. Chief and corroborative hydrogen bonds of the bisphenol A phenol-hydroxyl group with Arg316 and Glu275 residues.
Liu X; Matsushima A; Okada H; Tokunaga T; Isozaki K; Shimohigashi Y
FEBS J; 2007 Dec; 274(24):6340-51. PubMed ID: 18005256
[TBL] [Abstract][Full Text] [Related]
19. Network analysis of protein structures identifies functional residues.
Amitai G; Shemesh A; Sitbon E; Shklar M; Netanely D; Venger I; Pietrokovski S
J Mol Biol; 2004 Dec; 344(4):1135-46. PubMed ID: 15544817
[TBL] [Abstract][Full Text] [Related]
20. Detection of 3D atomic similarities and their use in the discrimination of small molecule protein-binding sites.
Najmanovich R; Kurbatova N; Thornton J
Bioinformatics; 2008 Aug; 24(16):i105-11. PubMed ID: 18689810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
